STING-IN-18
STING-IN-18 is an orally active STING inhibitor. STING-IN-18 exhibits an IC50 of 86 nM against STING in murine RAW-LuciaTM ISG cells. STING-IN-18 inhibits STING activation and blocks downstream signaling pathways. STING-IN-18 suppresses kidney injury and inflammation. STING-IN-18 can be used for the research of autoimmune and inflammatory diseases.
For research use only. We do not sell to patients.
- Formula: C18H18FN5O
- Molecular Weight:339.37
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
STING-IN-18 (Compound QQ21) (1-5 μM; 14 h) inhibits the downstream signaling pathway of STING in RAW264.7 and THP-1 cells, and reduces the levels of IFNβ, TNFα, IL6 and CXCL10[1].
STING-IN-18 (2.5-5 μM; 24 h) reduces Cisplatin (HY-17394)-induced ROS production in THP-1 cells in a concentration-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RAW264.7 and THP-1
-
Concentration:1 and 5 μM
-
Incubation Time:Pretreated for 2 h, and treated with MSA-2 (HY-136927) for 14 h.
-
Result:Inhibited the mRNA levels of FNβ, TNFα, IL6, and CXCL10 in a dose-dependent manner.
In Vivo
STING-IN-18 (10 mg/kg; i.p.; 4 days) effectively alleviates Cisplatin (HY-17394)-induced acute kidney injury in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 J (male, 8 weeks old, acute kidney injury model induced by Cisplatin (HY-17394) )[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; daily; 4 days
-
Result:Alleviated kidney enlargement and ischemic symptoms. Reduced elevated blood urea nitrogen (BUN) and serum creatinine levels.
Inhibited cisplatin-induced upregulation of IFNβ and TNFα protein levels.
Mitigated renal injury observed via H&E staining.
Chemical Information
-
Molecular Weight 339.37
-
Formula C18H18FN5O
-
SMILES
FC1=CC=C2C(C(NC(C3=NC=C(NC4CCCC4)N=C3)=O)=CN2)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Nephrotoxicity Study
This protocol assesses nephrotoxicity by combining functional kidney injury readouts, urinary/tissue injury biomarkers, and renal histopathology. Serum creatinine and BUN reflect impaired kidney function, while KIM-1, NGAL, clusterin, osteopontin, IL-18, cystatin C, nephrin, Oat5, urinary protein, glucose, and alkaline phosphatase have been used to detect tubular injury in cisplatin-, gentamicin-, and acetaminophen-induced nephrotoxicity models.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)